SEC Form 4 · accession 0001140361-16-080948
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean A. McCarthy
Officer — President and CEO · Director
Period of report
Sep 26, 2016
Accepted (ET)
Sep 28, 2016 · 7:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.945 | Sep 26, 2016 | A | 48,379 | A | — | Feb 25, 2023 | Common Stock | 48,379 | 48,379 | D |
| Stock Option (Right to Buy)F2 | $1.5749 | Sep 26, 2016 | A | 122,424 | A | — | Feb 8, 2025 | Common Stock | 122,424 | 122,424 | D |
Explanation of responses
- F1On February 26, 2013, the Reporting Person was granted an option to purchase 96,758 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). 50% of the Performance Option previously vested upon achievement of the first performance milestone. On September 26, 2016, the second performance milestone was achieved resulting in vesting of the remaining 50% of the Performance Option.
- F2On February 9, 2015, the Reporting Person was granted an option to purchase 122,424 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in full upon achievement of a certain performance-based milestone (the "Performance Option"). On September 26, 2016, the performance milestone was achieved resulting in 100% of the Performance Option vesting.